Stocks and Investing
Stocks and Investing
Tue, January 24, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (TSVT) at Buy with Decreased Target to $28 on, Jan 24th, 2023
Matthew Harrison of Morgan Stanley, Maintained "2seventy bio, Inc." (TSVT) at Buy with Decreased Target from $29 to $28 on, Jan 24th, 2023.
Matthew has made no other calls on TSVT in the last 4 months.
There are 3 other peers that have a rating on TSVT. Out of the 3 peers that are also analyzing TSVT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $28 on, Friday, January 20th, 2023
- Daina Graybosch of "SVB Leerink" Maintained at Buy with Decreased Target to $34 on, Tuesday, January 10th, 2023
- Kelsey Goodwin of "Guggenheim" Initiated at Strong Buy and Held Target at $30 on, Monday, October 31st, 2022
Contributing Sources